There are 2789 resources available
689P - Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC)
Presenter: Lisa Kinget
Session: ePoster Display
690P - Comprehensive genomic profiling (CGP) of VHL mutated and VHL wild type clear cell renal cell carcinoma (ccRCC)
Presenter: Gennady Bratslavsky
Session: ePoster Display
790P - Extracellular traps of the circulating neutrophils in CIN and cervical cancer
Presenter: Tatyana Abakumova
Session: ePoster Display
692P - Characterization of the tumor immune microenvironment in early-stage clear cell renal cell carcinoma (ccRCC): Prognostic value of an M0-macrophage enriched subtype
Presenter: Mark Farha
Session: ePoster Display
693P - Plasma exosome microRNA-155-3p expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: Potential biomarker of response to systemic therapy
Presenter: Maryam Soleimani
Session: ePoster Display
694P - Methylthioadenosine phosphorylase (MTAP) deletion is more common in sarcomatoid (srcRCC) than in clear cell renal cell carcinoma (ccRCC)
Presenter: Andrea Necchi
Session: ePoster Display
695P - Drug-drug interactions between pazopanib and proton pump inhibitors may significantly affect clinical outcome of patients affected by metastatic renal cell carcinoma
Presenter: Marzia Del Re
Session: ePoster Display
696P - Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)
Presenter: Sara Elena Rebuzzi
Session: ePoster Display
697P - Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N)
Presenter: Carolina Alves Costa Silva
Session: ePoster Display
698P - Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma
Presenter: Jonathan Rosenberg
Session: ePoster Display